AZD4635 + docetaxel

AZD4635 + docetaxel is a combination regimen consisting of AZD4635, a selective, oral adenosine A2A receptor antagonist, and docetaxel, a microtubule inhibitor chemotherapeutic agent. AZD4635 blocks adenosine-mediated immunosuppression in the tumor microenvironment, thereby enhancing anti-tumor immune responses. Docetaxel disrupts microtubule function and induces cell cycle arrest and apoptosis in rapidly dividing cancer cells. The combination has been investigated for synergistic antitumor activity, especially in advanced solid tumors and prostate cancer, though clinical studies of AZD4635 primarily report combinations with immune checkpoint inhibitors and do not widely report direct combinations with docetaxel[1][2].

Other names

AZD4635AZD-4635AZD 4635docetaxel